

Caterina Ilari

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4799522/caterina-ilari-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

307
papers

6,527
citations

35
h-index

74
g-index

329
ext. papers

8,176
ext. citations

5.1
avg. IF

5.4
L-index

#	Paper	IF	Citations
307	Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia.. <i>Leukemia and Lymphoma</i> , 2022 , 1-3	1.9	
306	Prediction of outcomes in cll patients treated with ibrutinib: validation of current prognostic models and development of a simplified three-factor model.. <i>American Journal of Hematology</i> , 2022	7.1	2
305	Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial.. <i>American Journal of Hematology</i> , 2022 ,	7.1	
304	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study.. <i>Frontiers in Oncology</i> , 2022 , 12, 839915	5.3	0
303	Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall.. <i>British Journal of Haematology</i> , 2022 ,	4.5	
302	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021 , 35, 3444-3454	10.7	11
301	Reduced mortality from KPC-K.pneumoniae bloodstream infection in high-risk patients with hematological malignancies colonized by KPC-K.pneumoniae. <i>BMC Infectious Diseases</i> , 2021 , 21, 1079	4	2
300	Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy. <i>Blood</i> , 2021 , 138, 3755-3755	2.2	
299	Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study. <i>Blood</i> , 2021 , 138, 3408-3408	2.2	1
298	A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments. <i>Blood</i> , 2021 , 138, 704-704	2.2	
297	Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.. <i>Frontiers in Oncology</i> , 2021 , 11, 804714	5.3	2
296	Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia. <i>Haematologica</i> , 2021 ,	6.6	1
295	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2021 , 196, 559	4.5	5
294	INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021 ,	7.8	5
293	Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab. <i>Annals of Hematology</i> , 2021 , 100, 2117-2119	3	2
292	Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2261-2266	1.9	
291	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021 , 39, 326-335	1.3	3

290	Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2021 , 100, 1213-1219	3	2
289	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021 , 11, 637186	5.3	4
288	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021 , 96, E306-E310	7.1	3
287	The current role of interferon in hairy cell leukaemia: clinical and molecular aspects. <i>British Journal of Haematology</i> , 2021 , 194, 78-82	4.5	5
286	The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation. <i>Haematologica</i> , 2021 ,	6.6	8
285	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021 , 137, 3507-3517	2.2	12
284	Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience. <i>British Journal of Haematology</i> , 2021 , 195, 278-283	4.5	0
283	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021 , 13,	6.6	5
282	Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. <i>Blood</i> , 2021 , 138, 2290-2293	2.2	3
281	Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints. <i>Cancer Journal (Sudbury, Mass)</i> , 2021 , 27, 320-327	2.2	0
280	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021 , 35, 235-238	10.7	11
279	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. <i>Haematologica</i> , 2021 , 106, 1559-1568	6.6	20
278	Very late acute myeloid leukemia relapse: clinical features, treatment and outcome. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1022-1025	1.9	1
277	Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 755-757	1.9	4
276	Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103163	7	5
275	Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy. <i>Leukemia and Lymphoma</i> , 2021 , 62, 828-836	1.9	4
274	Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial. <i>American Journal of Hematology</i> , 2021 , 96, 292-301	7.1	9
273	Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1026-1027	1.9	2

272	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021 , 106, 493-499	3.8	1
271	A multicenter total therapy strategy for adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. <i>Haematologica</i> , 2021 , 106, 1828-1838	6.6	8
270	Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2021 , 5, e543	0.3	7
269	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021 , 96, E168-E171	7.1	5
268	Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. <i>British Journal of Haematology</i> , 2021 , 193, 325-338	4.5	3
267	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. <i>Leukemia</i> , 2021 , 35, 2222-2232	10.7	3
266	Myeloid Sarcoma: Diagnostic and Treatment Tools from a Monocentric Retrospective Experience. <i>Acta Haematologica</i> , 2021 , 1-5	2.7	0
265	COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now. <i>Cancer Journal (Sudbury, Mass)</i> , 2021 , 27, 328-333	2.2	3
264	Emerging tyrosine kinase inhibitors for the treatment of adult acute lymphoblastic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2021 , 26, 281-294	3.7	0
263	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021 , 39, 570-574	1.3	2
262	Treatment of childhood acute lymphoblastic leukemia in Iraq: a 17-year experience from a single center. <i>Leukemia and Lymphoma</i> , 2021 , 1-10	1.9	
261	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021 , 11, 684621	5.3	1
260	Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia. <i>Hematological Oncology</i> , 2021 , 39, 680-686	1.3	2
259	COMPLEX KARYOTYPE IN UNFIT PATIENTS WITH CLL TREATED WITH IBRUTINIB AND RITUXIMAB. THE GIMEMA LLC1114 PHASE 2 STUDY. <i>Blood</i> , 2021 ,	2.2	2
258	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021 , 100, 2005-2014	3	3
257	Increased eryptosis in patients with primary antiphospholipid syndrome (APS): a new actor in the pathogenesis of APS. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 838-843	2.2	1
256	Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.. <i>American Journal of Hematology</i> , 2021 ,	7.1	3
255	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.. <i>Cancers</i> , 2021 , 14,	6.6	1

254	Does MRD have a role in the management of iNHL?. <i>Hematology American Society of Hematology Education Program</i> , 2021 , 2021, 320-330	3.1	0
253	Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study. <i>British Journal of Haematology</i> , 2020 , 190, e3-e5	4.5	17
252	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020 , 135, 1859-1869	2.2	45
251	Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2020 , 99, 2773-2777	3	1
250	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2020 , 99, 1525-1530	3	4
249	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020 , 10, 66	7	1
248	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020 , 136, 763-766	2.2	17
247	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020 , 34, 2260-2261	10.7	37
246	Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020 , 189, 826-843	4.5	8
245	Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 629-639	5.1	4
244	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020 , 34, 2354-2363	10.7	118
243	Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19. <i>British Journal of Haematology</i> , 2020 , 190, e214-e218	4.5	18
242	ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020 , 190, e346-e349	4.5	2
241	First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an "operational cure". <i>Lancet Haematology</i> , 2020 , 7, e182-e183	14.6	
240	Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2020 , 188, e101-e105	4.5	3
239	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). <i>Haematologica</i> , 2020 , 105, 2671-2674	6.6	
238	Biological and clinical implications of mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020 , 105, 448-456	6.6	35
237	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020 , 136, 47-49	2.2	

236	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020 , 136, 23-25	2.2	
235	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020 , 136, 47-48	2.2	
234	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. <i>Blood</i> , 2020 , 136, 30-31	2.2	
233	Mutations of the Exportin 1 (XPO1) Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. Training/Validation Study. <i>Blood</i> , 2020 , 136, 31-32	2.2	0
232	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. <i>Blood</i> , 2020 , 136, 45-46	2.2	
231	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020 , 136, 8-9	2.2	
230	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. <i>Blood</i> , 2020 , 136, 33-34	2.2	1
229	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020 , 136, 45-49	2.2	2
228	Long-Term Treatment of Hairy Cell Leukemia Patients with Interferon: Clinical and Molecular Aspects. <i>Blood</i> , 2020 , 136, 37-37	2.2	
227	Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. <i>British Journal of Haematology</i> , 2020 , 189, 853-859	4.5	6
226	Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. <i>Haematologica</i> , 2020 , 106, 1500-1503	6.6	1
225	MiroStudy, a FIL multicenter phase II trial combining local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e20073-e20073 ²		
224	Use of edoxaban for the treatment of venous thromboembolism in HIV-infected patients. <i>HIV Medicine</i> , 2020 , 21, e7	2.7	1
223	Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients. <i>Supportive Care in Cancer</i> , 2020 , 28, 4193-4199	3.9	11
222	The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. <i>Leukemia and Lymphoma</i> , 2020 , 61, 536-545	1.9	3
221	Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. <i>New England Journal of Medicine</i> , 2020 , 383, 1613-1623	59.2	103
220	Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. <i>Hematological Oncology</i> , 2020 , 38, 607-610	1.3	1
219	The advantages and risks of ruxolitinib for the treatment of polycythemia vera. <i>Expert Review of Hematology</i> , 2020 , 13, 1067-1072	2.8	1

218	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020 , 9, 8468-8479	4.8	8
217	Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma. <i>Hematological Oncology</i> , 2020 , 38, 698-704	1.3	1
216	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. <i>Blood Cancer Journal</i> , 2020 , 10, 92	7	5
215	A Rare Case of Coexisting Breast Cancer and Refractory Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2020 , 2020, 8893185	0.7	
214	Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. <i>Annals of Hematology</i> , 2020 , 99, 2405-2416	3	3
213	Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice. <i>Expert Review of Hematology</i> , 2020 , 13, 1311-1318	2.8	3
212	Platelet activation and multidrug resistance protein-4 expression in children and adolescents with different subtypes of primary thrombocythemia. <i>Haematologica</i> , 2020 , 105, e65-e67	6.6	1
211	Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with fusion transcript. <i>Leukemia and Lymphoma</i> , 2020 , 61, 469-472	1.9	10
210	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020 , 301, 163-166	3.2	13
209	Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy. <i>British Journal of Haematology</i> , 2020 , 188, 249-258	4.5	11
208	HIF-1 α s over-expressed in leukemic cells from -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020 , 105, 1042-1054	6.6	23
207	Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. <i>Leukemia</i> , 2020 , 34, 441-450	10.7	4
206	Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2020 , 26, 812-820	12.9	9
205	Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?. <i>Frontiers in Oncology</i> , 2019 , 9, 689	5.3	18
204	CMV Management with Specific Immunoglobulins: A Multicentric Retrospective Analysis on 92 Allografted Patients. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019 , 11, e2019048	3.2	4
203	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. <i>Annals of Hematology</i> , 2019 , 98, 1933-1936	3	2
202	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , 2019 , 121, 150-156	8.7	17
201	Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. <i>Annals of Hematology</i> , 2019 , 98, 1919-1925	3	8

200	Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia. <i>Acta Haematologica</i> , 2019 , 142, 185-186	2.7	1
199	Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2019 , 104, 2053-2060	6.6	39
198	Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. <i>Annals of Hematology</i> , 2019 , 98, 1891-1904	3	7
197	Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1224-1233	1.9	3
196	Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. <i>Hematological Oncology</i> , 2019 , 37, 291-295	1.3	10
195	Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2838-2840	1.9	16
194	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019 , 98, 1885-1890	3	10
193	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. <i>International Journal of Cardiology</i> , 2019 , 288, 124-127	3.2	13
192	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019 , 37, 418-423	1.3	2
191	The role of an accurate diagnosis of inherited thrombocytopenia as the basis for an effective treatment. A case of MYH9 syndrome treated with a TPO-RA. <i>Haemophilia</i> , 2019 , 25, e288-e290	3.3	2
190	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019 , 37, 296-302	1.3	33
189	Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease. <i>Leukemia and Lymphoma</i> , 2019 , 60, 274-276	1.9	1
188	Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances. <i>Frontiers in Oncology</i> , 2019 , 9, 726	5.3	36
187	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2368-2397	4.7	14
186	Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma. <i>British Journal of Haematology</i> , 2019 , 186, e217-e219	4.5	0
185	Maintenance therapy in AML: The past, the present and the future. <i>American Journal of Hematology</i> , 2019 , 94, 1254-1265	7.1	24
184	Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. <i>Hematological Oncology</i> , 2019 , 37, 368-374	1.3	7
183	Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome. <i>Hematological Oncology</i> , 2019 , 37, 652-654	1.3	10

182	Direct Oral Anticoagulants in Patients Affected by Major Congenital Thrombophilia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019 , 11, e2019044	3.2	14
181	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019 , 37, 508-512	1.3	3
180	Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. <i>British Journal of Haematology</i> , 2019 , 187, e8-e11	4.5	7
179	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019 , 11,	6.6	7
178	Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment. <i>Leukemia Research</i> , 2019 , 87, 106233	2.7	10
177	Incidence of Clinically Significant (≥ 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. <i>Oncology Research and Treatment</i> , 2019 , 42, 660-664	2.8	0
176	Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial. <i>Blood</i> , 2019 , 134, 740-740	2.2	23
175	Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy. <i>Blood</i> , 2019 , 134, 2888-2888	2.2	1
174	Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement. <i>Blood</i> , 2019 , 134, 3010-3010	2.2	
173	Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study. <i>Blood</i> , 2019 , 134, 2624-2624	2.2	
172	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. <i>Blood</i> , 2019 , 134, 3845-3845	2.2	1
171	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. <i>Hematology</i> , 2019 , 24, 337-348	2.2	33
170	Response to Comment by Amato T.. <i>Haematologica</i> , 2019 , 104, e541	6.6	
169	THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL. <i>Hematological Oncology</i> , 2019 , 37, 110-111	1.3	14
168	Aplastic Anemia and Good Syndrome in a Heavily Treated Stage IV Thymoma Patient: A Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2019 , 2019, 1910923	0.7	2
167	IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies. <i>Leukemia and Lymphoma</i> , 2019 , 60, 829-832	1.9	8
166	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2019 , 104, 312-318	6.6	33
165	BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?. <i>Cancer</i> , 2019 , 125, 194-204	6.4	34

164	Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia. <i>Expert Review of Hematology</i> , 2019 , 12, 81-87	2.8	7
163	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2019 , 54, 103-110	4.4	68
162	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019 , 98, 889-896	3	4
161	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018 , 36, 624-632	1.3	36
160	Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia. <i>Current Oncology Reports</i> , 2018 , 20, 23	6.3	15
159	Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2715-2718	1.9	1
158	Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review. <i>Haematologica</i> , 2018 , 103, e138-e140	6.6	3
157	Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. <i>Annals of Hematology</i> , 2018 , 97, 1577-1580	3	25
156	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018 , 103, 1209-1217	6.6	24
155	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018 , 32, 1869-1873	10.7	8
154	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. <i>British Journal of Haematology</i> , 2018 , 181, 229-233	4.5	25
153	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018 , 93, E159-E161	7.1	19
152	High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement. <i>Leukemia</i> , 2018 , 32, 1807-1810	10.7	11
151	Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. <i>Annals of Oncology</i> , 2018 , 29, 966-972	10.3	13
150	Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. <i>Oncolmmunology</i> , 2018 , 7, e1341032	7.2	9
149	Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases. <i>American Journal of Hematology</i> , 2018 , 93, E35-E37	7.1	12
148	Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. <i>Leukemia</i> , 2018 , 32, 543-546	10.7	2
147	Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2018 , 97, 1797-1802	3	14

146	Current and future therapeutic approaches for the treatment of follicular lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 931-941	3.5	
145	Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia. <i>Cancer Immunology Research</i> , 2018 , 6, 1110-1119	12.5	4
144	Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. <i>Haematologica</i> , 2018 , 103, 1889-1898	6.6	13
143	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018 , 93, E216-E219	7.1	9
142	Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. <i>Leukemia</i> , 2018 , 32, 1778-1786	10.7	20
141	Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. <i>European Journal of Haematology</i> , 2018 , 101, 578	3.8	2
140	Clinical Significance of Occult Central Nervous System Disease in Adult ACUTE Lymphoblastic Leukemia. a Multicenter, Report from the Campus ALL/Gimema Network. <i>Blood</i> , 2018 , 132, 658-658	2.2	2
139	Protective Role Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia: FOCUS on Subcutaneous Immunoglobulin Formulations. <i>Blood</i> , 2018 , 132, 4954-4954	2.2	1
138	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. <i>Blood</i> , 2018 , 132, 3118-3118	2.2	4
137	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018 , 132, 4412-4412	2.2	2
136	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018 , 132, 4277-4277	2.2	8
135	A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. <i>Blood</i> , 2018 , 132, 1834-1834	2.2	1
134	Intermittent Imatinib Mesylate in Children with Chronic Myeloid Leukemia: Results and Outcome. <i>Blood</i> , 2018 , 132, 4256-4256	2.2	1
133	Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. <i>Oncotarget</i> , 2018 , 9, 7534-7540	3.3	10
132	Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?. <i>Blood</i> , 2018 , 132, 1746-1746	2.2	
131	Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018 , 132, 3052-3052	2.2	
130	Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice. <i>Blood</i> , 2018 , 132, 5518-5518	2.2	
129	Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice. <i>Blood</i> , 2018 , 132, 1741-1741	2.2	

128	The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018 , 132, 1844-1844	2.2	
127	Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group. <i>Blood</i> , 2018 , 132, 5634-5634	2.2	
126	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort. <i>Blood</i> , 2018 , 132, 5464-5464	2.2	
125	Chemotherapy-free and reduced intensity approaches in elderly patients with B-lineage acute lymphoblastic leukemia. <i>European Journal of Internal Medicine</i> , 2018 , 58, 22-27	3.9	3
124	Real-Life Management of Children and Adolescents with Chronic Myeloid Leukemia: The Italian Experience. <i>Acta Haematologica</i> , 2018 , 140, 105-111	2.7	3
123	Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. <i>Annals of Hematology</i> , 2018 , 97, 1803-1808	3	8
122	Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. <i>Blood</i> , 2018 , 132, 405-412	2.2	22
121	Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2018 , 11, 601-611	2.8	8
120	Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. <i>Leukemia</i> , 2017 , 31, 997-1000	10.7	53
119	Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2017 , 92, 529-535	7.1	13
118	Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2017 , 57, 65-71	2.7	13
117	Diffuse large B-cell lymphoma genotyping on the liquid biopsy. <i>Blood</i> , 2017 , 129, 1947-1957	2.2	113
116	Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma. <i>British Journal of Haematology</i> , 2017 , 177, 588-596	4.5	28
115	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017 , 102, 1530-1536	6.6	12
114	Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia. <i>Leukemia</i> , 2017 , 31, 2552-2559	10.7	13
113	BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. <i>Blood</i> , 2017 , 129, 582-586		38
112	Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , 2017 , 4, e534-e543	14.6	22
111	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. <i>Advances in Therapy</i> , 2017 , 34, 2232-2273	4.1	227

110	Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life. <i>American Journal of Hematology</i> , 2017 , 92, E668-E670	7.1	4
109	Clinical relevance of silent red blood cell autoantibodies. <i>Haematologica</i> , 2017 , 102, e473-e475	6.6	7
108	The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017 , 92, E661-E664	7.1	11
107	Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?. <i>Expert Review of Hematology</i> , 2017 , 10, 761-774	2.8	11
106	Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 1473-1484	7.4	32
105	Very late relapse in a patient with acute promyelocytic leukemia (APL) rescued with a chemotherapy-free protocol. <i>Leukemia and Lymphoma</i> , 2017 , 58, 999-1001	1.9	4
104	Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. <i>Hematological Oncology</i> , 2017 , 35, 804-809	1.3	5
103	TPO-RAs in pTTP: description of a case series and analysis of predictive factors for response. <i>European Journal of Haematology</i> , 2017 , 98, 242-249	3.8	11
102	Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1640-1647	1.9	8
101	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017 , 130, 99-99	2.2	47
100	Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. <i>Oncotarget</i> , 2017 , 8, 25455-25468	3.3	7
99	COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi) A two-cohort phase II study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS7567-TPS7567	2.2	
98	Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. <i>Onc Immunology</i> , 2016 , 5, e1041701	7.2	29
97	Reappraising the timing of transplant for indolent non-Hodgkin lymphomas. <i>Expert Review of Hematology</i> , 2016 , 9, 951-64	2.8	1
96	Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2016 , 101, 951-8	6.6	14
95	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , 2016 , 128, 1362-73	2.2	88
94	Management of elderly and unfit patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2016 , 9, 1165-1175	2.8	4
93	The antileukemic potential of natural killer cells. <i>Immunotherapy</i> , 2016 , 8, 425-34	3.8	2

92	Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. <i>Leukemia Research</i> , 2016 , 44, 53-60	2.7	18
91	Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. <i>Leukemia</i> , 2016 , 30, 1615-9	10.7	11
90	CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. <i>Leukemia Research</i> , 2016 , 41, 36-42	2.7	27
89	Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a Home Care Unit program. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1716-8	1.9	2
88	Vemurafenib Plus Rituximab in Hairy Cell Leukemia: A Promising Chemotherapy-Free Regimen for Relapsed or Refractory Patients. <i>Blood</i> , 2016 , 128, 1214-1214	2.2	5
87	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. <i>Blood</i> , 2016 , 128, 2038-2038	2.2	2
86	Early Stage Follicular Lymphoma. Predictive Role of Minimal Residual Disease (MRD) and Impact of MRD-Driven Treatment with Radiotherapy and Rituximab on Clinical Outcome. <i>Blood</i> , 2016 , 128, 2959-2959	2.2	3
85	Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. <i>Oncotarget</i> , 2016 , 7, 7586-96	3.3	11
84	Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016 , 7, 20520-31	3.3	24
83	Comparative Analysis Between RQ-PCR and Digital Droplet PCR of BCL2/IGH Rearrangement in the Peripheral Blood and Bone Marrow of Early Stage Follicular Lymphoma. <i>Blood</i> , 2016 , 128, 5308-5308	2.2	
82	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. <i>Blood</i> , 2016 , 128, 3240-3240	2.2	
81	HIF-1 α upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. <i>Blood</i> , 2016 , 128, 305-305	2.2	
80	Assessment of Measures to Reduce Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab in the GREEN Study. <i>Blood</i> , 2016 , 128, 5589-5589	2.2	
79	Life-Threatening Autoimmune Hemolytic Anemia and Idiopathic Thrombocytopenic Purpura. Successful Selective Splenic Artery Embolization. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016 , 8, e2016020	3.2	1
78	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. <i>Oncotarget</i> , 2016 , 7, 13886-901	3.3	14
77	Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016 , 174, 541-9	4.5	42
76	Severe Thrombotic Complications in Congenital Afibrinogenemia: A Pathophysiological and Management Dilemma. <i>Seminars in Thrombosis and Hemostasis</i> , 2016 , 42, 577-82	5.3	15
75	Clinical characteristics and outcome of patients with autoimmune hemolytic anemia uniformly defined as primary by a diagnostic work-up. <i>American Journal of Hematology</i> , 2016 , 91, E319-20	7.1	

74	A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. <i>Haematologica</i> , 2016 , 101, 1544-1552	6.6	44
73	Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2685-8	1.9	14
72	Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2016 , 101, e135-8	6.6	30
71	RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. <i>Haematologica</i> , 2016 , 101, 941-50	6.6	30
70	The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPβ. <i>Leukemia</i> , 2015 , 29, 2442-5	10.7	23
69	Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group. <i>Haematologica</i> , 2015 , 100, e10-3	6.6	27
68	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015 , 373, 1733-47	59.2	215
67	Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study. <i>Leukemia Research</i> , 2015 , 39, 1382-8	2.7	24
66	The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , 2015 , 29, 503-7	10.7	62
65	Management of adult Ph-positive acute lymphoblastic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2015 , 2015, 406-13	3.1	29
64	Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. <i>Blood</i> , 2015 , 126, 1925-9	2.2	112
63	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 126, 1921-4	2.2	167
62	The pan-class I phosphatidylinositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. <i>Scientific Reports</i> , 2015 , 5, 18137	4.9	21
61	Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>American Journal of Hematology</i> , 2015 , 90, E181-2	7.1	2
60	Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. <i>Haemophilia</i> , 2015 , 21, 496-501	3.3	36
59	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. <i>Genes Chromosomes and Cancer</i> , 2015 , 54, 818-26	5	27
58	Enteropathy-associated T-cell lymphoma in childhood: a case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2743-6	1.9	2
57	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2015 , 16, 57-66	21.7	832

56	Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. <i>Leukemia</i> , 2015 , 29, 1360-5	10.7	41
55	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015 , 6, 32089-103	3.3	30
54	NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. <i>Oncotarget</i> , 2015 , 6, 42569-74	3.3	25
53	Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience. <i>Blood</i> , 2015 , 126, 2788-2788	2.2	
52	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014 , 89, 480-6	7.1	86
51	Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. <i>Leukemia</i> , 2014 , 28, 642-8	10.7	48
50	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. <i>Leukemia Research</i> , 2014 , 38, 198-203	2.7	4
49	Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. <i>Leukemia Research</i> , 2014 , 38, 194-7	2.7	17
48	Cytomegalovirus in bone marrow cells correlates with cytomegalovirus in peripheral blood leukocytes. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 2183-5	9.7	3
47	CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. <i>Blood</i> , 2014 , 123, 3677-9	2.2	20
46	Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. <i>Haematologica</i> , 2014 , 99, 1248-54	6.6	44
45	Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial. <i>Blood</i> , 2014 , 124, 150-150	2.2	2
44	Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer \square Olaptosed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma. <i>Blood</i> , 2014 , 124, 2111-2111	2.2	3
43	First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients. <i>Blood</i> , 2014 , 124, 797-797	2.2	9
42	Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7005-7005	2.2	9
41	Phase 3 study of oral lenalidomide as maintenance therapy for patients with B-cell chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS7125-TPS7125	2.2	1
40	Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. <i>ELife</i> , 2014 , 3,	8.9	37
39	Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 3687-3687	2.2	

38	Clinical Features and Prognostic Factors in Solitary Plasmacytoma: A Single Center Retrospective Study. <i>Blood</i> , 2014 , 124, 3455-3455	2.2	
37	Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2014 , 124, 1326-1326	2.2	
36	Bendamustine and Dexamethasone Is an Effective Salvage Regimen for Patient with Advanced Multiple Myeloma in a Home Care Unit Program. <i>Blood</i> , 2014 , 124, 5753-5753	2.2	
35	Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014 , 124, 295-295	2.2	1
34	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. <i>MAbs</i> , 2013 , 5, 826-37	6.6	83
33	Clinical implications of the molecular genetics of chronic lymphocytic leukemia. <i>Haematologica</i> , 2013 , 98, 675-85	6.6	58
32	Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. <i>PLoS Genetics</i> , 2013 , 9, e1003997	6	94
31	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. <i>Haematologica</i> , 2013 , 98, 1702-10	6.6	87
30	PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study. <i>Blood</i> , 2013 , 122, 405-405	2.2	3
29	Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. <i>Blood</i> , 2013 , 122, 770-770	2.2	2
28	Rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by sequential use of nilotinib and imatinib: A GIMEMA protocol LAL 1408.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7025-7025	2.2	0
27	Expanded Natural Killer Cells For The Control Of Minimal Residual Disease In Ph+ Acute Lymphoblastic Leukemia Patients. <i>Blood</i> , 2013 , 122, 2026-2026	2.2	
26	Modulation Of The Glycolytic Metabolism In Acute Myeloid Leukemia Cells. <i>Blood</i> , 2013 , 122, 5045-5045	2.2	
25	FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up Analysis. <i>Blood</i> , 2013 , 122, 1336-1336	2.2	
24	Splenectomy Is Still a Valid Option For Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2013 , 122, 5129-5129	2.2	
23	Management of adult patients with Philadelphia positive acute lymphoblastic leukemia. <i>Rinsho Ketsueki/the Japanese Journal of Clinical Hematology</i> , 2013 , 54, 1828-37	1.8	
22	The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1. <i>Leukemia Supplements</i> , 2012 , 1, S26-8	75	1
21	BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the second-generation TKI era.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 6531-6531	2.2	

20	B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 1780-1780	2.2	
19	Caring for patients with haematological malignancies. <i>Lancet Oncology, The</i> , 2011 , 12, 928-9	21.7	2
18	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood</i> , 2011 , 118, 6521-8	2.2	312
17	BRAF mutations in hairy-cell leukemia. <i>New England Journal of Medicine</i> , 2011 , 364, 2305-15	59.2	791
16	Acute lymphoblastic leukemia: age and biology. <i>Mental Illness</i> , 2011 , 3 Suppl 2, e2	0.9	6
15	The European Hematology Association: strengthening hematology in Europe and beyond. <i>Expert Review of Hematology</i> , 2011 , 4, 133-6	2.8	
14	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. <i>Blood</i> , 2011 , 118, 294-294	2.2	4
13	Subnetwork-Based Analysis of Chronic Lymphocytic Leukemia Identifies Pathways That Associate with Disease Progression,. <i>Blood</i> , 2011 , 118, 3564-3564	2.2	1
12	Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. <i>Annals of Oncology</i> , 2010 , 21, 1870-1876	10.3	100
11	Incidence and Predictors of Early Treatment-Related Mortality In Pediatric Acute Lymphoblastic Leukemia In Baghdad (Iraq). <i>Blood</i> , 2010 , 116, 2132-2132	2.2	1
10	A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. <i>Blood</i> , 2010 , 116, 2462-2462	2.2	5
9	GIMEMA-AIEOP AIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children: Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials. <i>Blood</i> , 2010 , 116, 871-871	2.2	4
8	Acute Erythroid Leukemia: A Distinctive Subtype of AML? Outcome and Prognostic Factors in Comparison with Non-M6 AML. The Gimema Experience.. <i>Blood</i> , 2009 , 114, 1019-1019	2.2	
7	CRLF2/JAK Signaling in Adult and Pediatric Acute Lymphoblastic Leukemia Is Highly Similar to BCR/ABL.. <i>Blood</i> , 2009 , 114, 3461-3461	2.2	
6	Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAI0201-B protocol. <i>Blood</i> , 2007 , 109, 3576-8	2.2	277
5	714 CONTROLLED RELEASE (CR) OXYCODONE FOR THE TREATMENT OF IATROGENIC NEUROPATHIC PAIN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES. <i>European Journal of Pain</i> , 2006 , 10, S186b-S186	3.7	
4	A broad and integrated diagnostic work-up for a modern management of Acute Lymphoblastic Leukemia (ALL). <i>Hematology</i> , 2005 , 10 Suppl 1, 55-62	2.2	0
3	IgVH mutations in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2005 , 90, 434-5	6.6	

- 2 Breast Cancer Resistance Protein (BCRP) in Adult Acute Lymphoblastic Leukemia Patients.. *Blood*, **2004**, 104, 1897-1897 2.2
- 1 Identification of a LOH Region on Chromosome 9p Associated with a Specific Gene Expression Signature in Adult B-Lineage ALL through Integration of High Density Microarray Expression and SNP Analyses.. *Blood*, **2004**, 104, 1119-1119 2.2